{"id":"1ed16c6325d8","type":"article","url":"https://hartvaat.nl/2026/01/27/colchicine-bij-acs-meta-analyse-van-alle-rct-s/","title":"Colchicine bij ACS: meta-analyse van alle RCT's","title_en":"Colchicine in acute coronary syndromes: a systematic review and meta-analysis of randomised controlled trials.","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog","internist"],"tags":["colchicine"],"journal":"Heart (British Cardiac Society)","doi":"10.1136/heartjnl-2025-325826","source_url":"https://doi.org/10.1136/heartjnl-2025-325826","authors":["Ramon Huntermann","Juan Peres de Oliveira","Lucas M Barbosa","Ivo Queiroz","Douglas Nunes Cavalcante","Caroline de Oliveira Fischer Bacca"],"significance":8,"published":"2026-01-27","source_date":"2026-01-27","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/colchicine-cardiovasculair/","https://hartvaat.nl/kennis/cardiometabool/inflammatie-en-atherosclerose/"],"congress":"","summary_en":"This updated meta-analysis of all colchicine trials in acute coronary syndromes confirmed significant MACE reduction with an acceptable safety profile. The anti-inflammatory concept in ACS is now supported by robust pooled evidence.","created":"2026-07-03T10:32:08Z","updated":"2026-07-03T13:31:06Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Geactualiseerde meta-analyse van alle colchicinetrials bij ACS bevestigde significante MACE-reductie. Het anti-inflammatoire concept is nu robuust bewezen voor secundaire CV-preventie.","abstract_original":"BACKGROUND: Acute coronary syndrome (ACS) is a global leading cause of morbidity, with residual inflammation contributing to recurrent events. Colchicine has been proposed as an adjunct therapy, but its efficacy remains uncertain. METHODS: We performed a systematic review and meta-analysis. PubMed, Embase and Cochrane databases were searched for randomised controlled trials (RCTs) data comparing colchicine versus placebo in ACS. Risk ratio (RR) and mean difference with 95% CIs were computed for binary and continuous outcomes, respectively. Primary outcomes were adverse cardiovascular events (ACEs), mortality and safety. Random-effects models were used for pooled estimates. RESULTS: Seventeen RCTs comprising 14 794 patients were included, of whom 7390 (50%) were randomised to colchicine. The mean patient age across the studies ranged from 54 to 63 years, in a follow-up period ranging from 5 days to 12 months. Colchicine reduced the incidence of recurrent ACS (RR 0.41, 95% CI 0.19 to 0.92; p=0.03; I²=55%) and unstable angina (RR 0.27, 95% CI 0.11 to 0.63; p<0.01; I²=0%). No meaningful differences were observed in all-cause mortality (RR 0.95, 95% CI 0.79 to 1.14; I²=12%), cardiovascular death (RR 1.03, 95% CI 0.82 to 1.30; I²=0%) or ACE (RR 0.77, 95% CI 0.59 to 1.01; p=0.05; I²=58%). Subgroup analyses suggested a dose-dependent effect, with 0.5 mg/day potentially reducing ACE (RR 0.63, 95% CI 0.45 to 0.88; I²=41%), but higher doses increasing gastrointestinal symptoms. CONCLUSION: Low-dose colchicine may reduce recurrent ischaemic events in ACS, but evidence remains uncertain due to heterogeneity and limited long-term data. Safety and efficacy in women and optimal dosing require further investigation. TRIAL REGISTRATION NUMBER: CRD42024627348."}